Preclinical experimentation and clinical research
Prognostic value of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 Trial
C. Morvant, C. Bailly, T. Carlier, G. Frecon, F. Kraeber-Bodéré, S. Le Gouill, E. Macintyre, C. Bodet-Milin,
J. Nucl. Med. Meeting Abstracts, SNM congress 2022, Vancouver, CanadaTargeted Alpha-Therapy for the treatment of Acute Myeloid Leukemia
Sorin M, Gouard S, Marionneau-Lambot S, Eychenne R, Maingueneau C, Ligeour M, Guilloux Y, Allard M, Guérard F, Chérel M, Gaschet J
15th Workshop New modalities in Cancer Imaging and Therapy, Erquy, France, october 5-8 2022Development and PET/CT preclinical evaluation of anti-CXCR4 antibody in triple-negative breast cancer (TNBC) murine model
Métivier C, El Ayoubi N, Le Saëc P, Garcion E, Tripier R, Haddad F, Chérel M, Huclier S, Faivre-Chauvet A, Rbah-Vidal L
15th Workshop New modalities in Cancer Imaging and Therapy, Erquy, France, october 5-8 2022Neutral Copper(II) TE1PA-based chelate for 64Cu-PET imaging : when an additional carboxyl group makes the difference
Pineau J, Lima LMP, Marionneau-Lambot S, Le Saëc P, Faivre-Chauvet A, Zeevaart JR, Driver CHS, Le Bris N, Tripier R
15th Workshop New modalities in Cancer Imaging and Therapy, Erquy, France, october 5-8 2022Evaluation théranostique d’un anticorps radiomarqué au cuivre-64 dans un modèle murin de myélome multiple.
Métivier C, Le Saëc P, Marionneau-Lambot S, Chauvet C, Hofgaard PO, Bogen B, Gaschet J, Tripier R, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L
15èmes Journées annuelles du Cancéropôle Grand-Ouest, Angers, France, July 1-2 2021Theranostic evaluation of a copper-64 radiolabelled antibody in a mouse model of multiple myeloma
Métivier C, Le Saëc P, Marionneau-Lambot S, Chauvet C, Hofgaard PO, Bogen B, Gaschet J, Tripier R, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L
14th Workshop Adaptation of the tumour and its ecosystem to radiotherapies, Le Bono, France, September 22-25 2021PET imaging of multiple myeloma: Comparison of 89Zr- and 64Cu-labeled anti-CD138 conjugates to 64CuCl2 and 18F-FDG in a preclinical syngeneic model. Bailly C, Gouard S, Chalopin B, Carlier T, Maurel C, Remaud-Le Saëc P, Bourgeois M, Chouin N, Tripier R, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Bodet-Milin C, Chérel M, 7th international workshop on PET in lymphoma and myeloma PIM, Menton, France, October 5-6 2018
Preliminary results of prognostic added value of PET textural features at diagnosis in multiple myeloma with a long-term follow-up, Carlier T, Jamet B, Bailly C, Touzeau C, Moreau P, Bodet-Milin C, Kraeber-Bodéré F, 7th international workshop on PET in lymphoma and myeloma PIM, Menton, France, October 5-6 2018
A population pharmacokinetics approach to evaluate the impact of the antibody dose in a context of lymphoma radioimmunotherapy (RIT) on dogs, Morio-Etienne F, Rajaud M, Becavin S, Piccirillo E, Touzot-Jourde G, Vidal A, Bourgeois M, Nguyen F, Abadie J, Varmenot N, Ferrer L, Bodet-Milin C, Ibisch C, Barbet J, Davodeau F, Chouin N, EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018